Search | Clinical Trials Finder

Conditions: Overactive Bladder
Interventions: Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification; Drug · Behavioral
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride; Drug
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Conditions: Pelvic Organ Prolapse
Interventions: Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex; Drug · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions: solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more

Conditions: Urinary Incontinence, Parkinson's Disease
Interventions: Solifenacin Succinate (VESIcare), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 30 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neurogenic Detrusor Overactivity, Pediatric
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 6 Months to 4 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Urethral Sphincter Activity
Interventions: Pseudoephedrine, Tamsulosin, Imipramine, Cyclobenzaprine, Lactose capsule, Solifenacin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 51 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neurogenic Detrusor Overactivity
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Tarrytown, New York • Cincinnati, Ohio

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 75
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Urinary Incontinence, Urgency Urinary
Interventions: Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Over-Active Bladder
Interventions: Solifenacin succinate, Placebo; Drug
Lead sponsor: Advanced Research Network; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin Succinate Suspension, Placebo, Urotherapy; Drug · Behavioral
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Albany, New York

Conditions: Hot Flashes, Breast Cancer
Interventions: solifenacin, Clonidine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Urinary Bladder, Overactive
Interventions: solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 198
States / cities: Bay Minette, Alabama • Birmingham, Alabama • Decatur, Alabama + 171 more

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: Solifenacin Succinate Formulation A, Solifenacin Succinate Formulation B, Solifenacin Succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: solifenacin succinate suspension, solifenacin succinate tablet; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin succinate suspension; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Overactive Bladder
Interventions: Solifenacin, Placebo; Drug · Other
Lead sponsor: Cleveland Clinic Florida; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Lower Urinary Tract Symptoms
Interventions: Tamsulosin, Solifenacin; Drug
Lead sponsor: Timothy Boone, MD, PhD; Other
Eligibility: 45 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post-micturition Incontinence, Incontinence
Interventions: solifenacin; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

Anticholinergic vs. Botox Comparison Study

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

Over Active Bladder Patients Having Sling Surgery

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

The Effect of Solifenacin on Post Void Dribbling in Women